NASDAQ · VIVS

VivoSim Labs, Inc.

$0.42 -$0.03 (-6.91%) 1D After hours

Key Metrics

$1.57M
Market cap
P/E · TTM
$131.00K
Revenue · TTM
−$13.84M
Net income
EPS · TTM $-9.46
Dividend yield
Free cash flow −$10.83M
Beta · 1Y 1.18
EBITDA · TTM −$11.27M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 30 high, the share price fell 86%.

    Peak close $2.92 on Jan 30; trough close $0.42 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -86%
  • Jul 16
    The stock moved -28.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 16
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jan 30
    The stock moved +71.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jan 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.57M
Enterprise value
Shares outstanding3.5M
52-wk range$0.41 – $5.30
Avg volume · 20D1.2M
Net cash
Book value / share$-0.75
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About VivoSim Labs, Inc.
IPO dateAug 16, 2011
Employees15

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S12.00
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -8,768.7%
Net -10,567.2%
FCF -8,264.9%
ROE / ROIC 1,259.6% · 187.6%

Financial Health

Current ratio2.38
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.84M

Cash Flow · TTM

Operating CF −$10.83M
Capex $0
Free cash flow −$10.83M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-71.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings